Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer overall and live longer without the cancer growing or spreading than people who receive chemotherapy.
Administered via intravenous (IV) infusion every 3 weeks (q3w) until disease progression, unacceptable adverse events (AEs), or other cessation of treatment
Administered via IV infusion q3W until disease progression, unacceptable adverse events (AEs), or other cessation of treatment
Oral tablet administered once per day or per approved product label
Before administering each dose of I-DXd, premedication is required for prevention of nausea and vomiting with a 2 or 3 drug combination regimen (eg, corticosteroids with either a 5-HT3 receptor antagonist or an NK-1 receptor antagonist and other drugs as indicated) per approved product label
Berazategui, Buenos Aires, Argentina
Study Coordinator · +541142262013
Mar del Plata, Buenos Aires, Argentina
Study Coordinator · +5491132661847
Mar del Plata, Buenos Aires, Argentina
Study Coordinator · +541132218900
La Rioja, Argentina
Study Coordinator · +543804693919
Mendoza, Argentina
Study Coordinator · +542614252575
Salta, Argentina
Study Coordinator · +5403874227282